Form 4: Teladoc Health Executive Daniel Trencher Reports Stock Transactions
SEC Form 4 Filing
Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.
Summary
- Daniel Trencher, Chief Strategy Officer of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- On August 30, 2024, Trencher acquired shares through the conversion of performance stock units (951 shares) and restricted stock units (1,179 and 2,790 shares).
- On September 3, 2024, Trencher disposed of 1,777 shares of common stock at a price of $7.164 per share.
- These transactions resulted in Trencher holding 31,465 shares of common stock directly.
- Trencher also holds derivative securities, including 5,706 performance stock units and 19,101 restricted stock units.
- The sale of shares was to cover tax withholding obligations related to the vesting of performance stock units and restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions appear to be routine and related to vesting schedules and tax obligations.
Industry Context
Executive stock transactions are a routine part of corporate governance and provide insights into an executive's perspective on the company's performance and future prospects. It is important to consider the overall context of these transactions, including the executive's compensation package and the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Reporting person was granted 14,149 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 33,482 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | One-third of performance stock units vested. |
| 08/30/2024 | Acquisition of shares through conversion of performance stock units and restricted stock units. |
| 09/03/2024 | Sale of 1,777 shares of common stock at $7.164 per share. |
| 09/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.